MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2967/jnumed.125.270233

Медицинская библиотека · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026

Malignancy Detection Rates of [68Ga]Ga-SSO120 PET/CT in Patients with Small Cell Lung Cancer and Large Cell Neuroendocrine Lung Cancer.

Christensen Tine N, Langer Seppo W, Dejanovic Danijela, Gillings Nicholas, Madsen Jacob, Persson Gitte, Keller Sune H, Albrecht-Beste Elisabeth, Fischer Barbara M

СтатьяКлиническое исследование II фазыПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

The primary aim of this study was to investigate the malignancy detection rate of [68Ga]Ga-SSO120 ([68Ga]Ga-satoreotide trizoxetan) PET/CT in patients with small cell lung cancer (SCLC) and large cell neuroendocrine lung cancer (LCNEC). Secondary aims included investigations of lesion-based detection rates and quantification.

Methods

In this prospective, phase 2, cross-sectional imaging trial, 21 [68Ga]Ga-SSO120 PET/CTs were performed for 19 patients. Overall detection rates, lesion-based detection rates, and number of identified lesions were compared between [68Ga]Ga-SSO120 PET and CT. The [68Ga]Ga-SSO120 SUVmax, SUVpeak, SUVmean, and tumor-to-liver ratios in malignant lesions and selected normal tissue were quantified.

Results

Nineteen patients (16 with SCLC, 2 with LCNEC, and 1 with combined SCLC/LCNEC) were scanned during palliation chemotherapy (n = 11) or surveillance (n = 8). [68Ga]Ga-SSO120-detectable lesions were identified in 18 patients (95%). Sensitivity in the lungs, regional lymph nodes, and extrathoracic regions was 82%, 83%, and 93%, respectively. [68Ga]Ga-SSO120 PET detected significantly fewer lesions than did CT (P = 0.037), particularly small lung lesions, regional lymph nodes, and liver lesions. In contrast, [68Ga]Ga-SSO120 PET identified 10 additional metastases in 5 patients (bone, 7; cerebellum, 1; subcutaneous, 2). SUVmax (median, 7.4; range, 4.6-26.4) was not significantly associated with time since diagnosis, time since last chemotherapy, number of treatment cycles, or current progression.

Conclusion

[68Ga]Ga-SSO120 PET/CT successfully visualized SCLC and LCNEC lesions during and after chemotherapy. Therapeutic studies with [177Lu]Lu-SSO110 ([177Lu]Lu-satoreotide tetraxetan), the theranostic companion of [68Ga]Ga-SSO120, PET are warranted.

Для цитирования: Christensen Tine N, Langer Seppo W, Dejanovic Danijela, Gillings Nicholas, Madsen Jacob, Persson Gitte, Keller Sune H, Albrecht-Beste Elisabeth, Fischer Barbara M. Malignancy Detection Rates of [68Ga]Ga-SSO120 PET/CT in Patients with Small Cell Lung Cancer and Large Cell Neuroendocrine Lung Cancer.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2026. DOI: 10.2967/jnumed.125.270233.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.